Kathleen Goin sold $371k of PVLA
Chief Operating Officer at PALVELLA THERAPEUTICS, INC.. 4,302 shares at an average of $86.23, traded Nov 19, 2025, filed Nov 21, 2025.
Score components
- +20RoleCOO
- +15Trade size$371k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-115017, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | MOption exercise Common Stock10b5-1 | +2,154 | $7.14 | $15k | 2,154 | Nov 21, 2025 |
| Nov 19, 2025 | MOption exercise Common Stock10b5-1 | +2,148 | $9.08 | $20k | 4,302 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stock10b5-1 | -1,500 | $85.72 | $129k | 2,802 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stock10b5-1 | -2,802 | $86.51 | $242k | 0 | Nov 21, 2025 |
| Nov 19, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,154 | $0.00 | $0 | 23,705 | Nov 21, 2025 |
| Nov 19, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,148 | $0.00 | $0 | 23,628 | Nov 21, 2025 |
Related signals
Other insiders at PALVELLA THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | PALVELLA THERAPEUTICS, INC. | Kathleen Goin Chief Operating Officer | $655k 4,302 shares | -100% | |
| 40Moderate | PALVELLA THERAPEUTICS, INC. | George M Jenkins director | $4.2M 27,500 shares | -15% | |
| 42Moderate | PALVELLA THERAPEUTICS, INC. | Christopher P Kiritsy director | $49k 313 shares | -56% | |
| 21Weak | PALVELLA THERAPEUTICS, INC. | Kathleen Goin Chief Operating Officer | $415k 4,302 shares | -100% | |
| 29Weak | PVLAbuy PALVELLA THERAPEUTICS, INC. | George M Jenkins director | $101k 4,990 shares | +3% | |
| 22Weak | PVLAbuy PALVELLA THERAPEUTICS, INC. | George M Jenkins director | $52k 4,000 shares | +2% | |
| 23Weak | PVLAbuy PALVELLA THERAPEUTICS, INC. | James A Geraghty director | $1 1 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.